Tucatinib: First Approval
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01340-w
Abstract: Tucatinib is an oral, small molecule, selective HER2 inhibitor initially developed by Array BioPharma (a subsidiary of Pfizer) and subsequently developed by Seattle Genetics for the treatment of HER2-positive solid tumours, including breast cancer and… read more here.
Keywords: her2 positive; first approval; breast cancer; cancer ... See more keywords
Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2022.2048862
Abstract: Abstract Context Tucatinib (CYP2C8 substrate) and quercetin (CYP2C8 inhibitor) are two common drugs for the treatment of cancer. However, the effect of quercetin on the metabolism of tucatinib remains unknown. Objective We validated a sensitive… read more here.
Keywords: quercetin; effect quercetin; tucatinib; evaluation inhibitory ... See more keywords
Abstract PO3-18-11: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po3-18-11
Abstract: Background: Patients with HER2+ early breast cancer (EBC) and invasive residual disease (RD) after neoadjuvant therapy (NAT) have a higher risk of relapse than patients who have a pathologic complete response (pCR). Escalation of therapy… read more here.
Keywords: cancer; breast cancer; tucatinib; dm1 ... See more keywords
Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial.
Sign Up to like & getrecommendations! Published in 2025 at "BMC cancer"
DOI: 10.1186/s12885-025-15224-3
Abstract: Approximately 30-50% of patients with HER-2 + breast cancer develop brain metastases (BM). Stereotactic radiosurgery (SRS) is frequently used for local disease control. Tucatinib, an oral HER-2-selective tyrosine kinase inhibitor, has been demonstrated to be safe and… read more here.
Keywords: cancer; breast cancer; trial; tucatinib ... See more keywords
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.20.00775
Abstract: PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of… read more here.
Keywords: her2 positive; breast cancer; tucatinib; positive breast ... See more keywords
Development and validation of an LC-MS/MS method for pharmacokinetic assessment of tucatinib in rat plasma
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Applied Pharmaceutical Science"
DOI: 10.7324/japs.2025.202389
Abstract: Tucatinib, a selective HER2 tyrosine kinase inhibitor demonstrating unique survival benefits for HER2-positive breast cancer patients, can be precisely measured in rat plasma using a validated LC-MS/MS method. To ensure reliable quantification, the method incorporates… read more here.
Keywords: validation; method; tucatinib; rat plasma ... See more keywords